The Bayer pharmaceutical giant announced the lunar that will produce from 2022 the vaccine against coronavirus that is developing the German company CureVac.
“My alegra announces that we need the capacity to produce the CureVac base based on the ARNm“, affirmed by the manager of the Bayer pharmaceutical sector, Stefan Oelrich, and agrees that the company’s objective is to produce 160 million doses in the first 12 months.
“Everything is necessary to increase the availability of vacancies”, añadió Oelrich.
These capacities are summed up in CureVac’s existing production of 300 million of this dose and one million million in 2022, declaration Franz-Werner Haas, Director General of CureVac, which is currently undergoing phase 3 vaccine clinicians.
It is currently in “certification process”, signed the Minister of Health, Jens Spahn, in the press conference.
According to the Minister, the production of the large space of the vacancy is guaranteed in the presence of possible changes or the need for a second vacancy within one or more years.
Bayer and the CureVac laboratory, located in Tubinga, will announce another association to accelerate the development of vacancies.